Key words: pantoprazole; renal impairment; haemodialysis; proton-pump inhibitor Background. Pantoprazole is a selective inhibitor of the gastric H+/K+-ATPase with a low potential to interact with the cytochrome P450 enzyme system.
could be expected that renal impairment would also Study design and medication not influence the pharmacokinetics of pantoprazole to
The study was conducted as a randomized two-period crossa clinically relevant degree. Due to the high protein over. Each subject was given two single i.v. doses (2-min binding of pantoprazole no relevant influence of injection) of 40 mg pantoprazole (Byk Gulden, Konstanz, haemodialysis on its pharmacokinetics was anticipated, Germany), one dose on the day before a regular haemodiabut the metabolites might behave differently. There-lysis (Study day A, during a short dialysis free interval of fore, it was the aim of this study to investigate the 24 h) and one dose on a haemodialysis day (day B, following pharmacokinetics of pantoprazole and its main meta-a dialysis-free interval of 48 h). All subjects received immedibolite M2 in patients with end-stage renal failure ately before initiation of haemodialysis 3000 IE heparin and undergoing regular haemodialysis.
during the haemodialysis procedure 1000 IE heparin per hour. The wash-out period between the two i.v. doses was at least 5 days, but not more than 14 days.
Venous blood was withdrawn from the arm opposite to
Subjects and methods
the arm with the shunt. During haemodialysis, blood was taken from the inflow line to the dialyser (Fresenius A 2008 Ethics and a capillary dialyser cuprophan 1.3 mO surface area). Three millilitres of blood were withdrawn before and at 0.25, The study protocol was approved by an independent ethics 0.5, 1, 2, 3, 4 h, and at the end of haemodialysis before committee and all subjects gave their written informed con-reinfusion (day B only) and at 6, 8, 10, 12 and 24 h using sent prior to the start of the study.
NH 4 -heparinized syringes. The blood was centrifuged to provide plasma which was stored immediately at −20°C.
Twenty-four-hour urine was collected on both study days.
Subjects
In order to avoid degradation of pantoprazole or metabolite M2, the urine was stabilized with 10 ml each of 8.4% Eight subjects (5 m/3 f ) with end-stage renal failure and NaHCO 3 solution which was placed in the bottles before normal findings associated with stable renal impairment who collection. During the 24-h urine collection the urine bottles had been on regular dialysis for at least 3 months and treated were stored in a refrigerator. At the end of the collection with constant medication entered the study (see Table 1 ).
period, the urine volume was determined and corrected for Exclusion criteria were infectious diseases, hypertension, the 10 ml of added sodium bicarbonate. An aliquot of 50 ml encephalopathy, bilirubin >2 mg/dl, haemoglobin <8 g/dl, was immediately deep frozen and stored at −20°C pending serum albumin <30 g/l, Quick <50%, thrombocytes analysis. The creatinine concentration and the creatinine <50 000/ml, and treatment with antiulcer drugs, cyclosporine clearance were determined. or anti-inflammatory drugs within 2 weeks prior to the start At each of the scheduled time points 0, 0.5, 1, 2, 3, 4 h of the study.
and at the end of haemodialysis (on day B only), 50 ml of All subjects received water-soluble vitamins after the the dialysis fluid were collected, immediately deep frozen, haemodialysis and calcium-containing phosphate binders, and stored at −20°C pending analysis. four of them additionally needed aluminium-containing phosphate binders (subjects 2, 4, 5 and 7). Erythropoietin was injected s.c. after the haemodialysis in a weekly dosage
Pantoprazole and metabolite M2 concentrations in
between 2000 and 6000 IE (except subjects 5 and 8), oral iron salts were given to subjects 1 and 6. Subjects 2 and 5 plasma, urine, and dialysate were treated with calcitriol (0.25 and 0.5 mg/day, respectively) as well as with acetylsalicylic acid (100 mg/day). All subjects Determination of plasma concentrations of pantoprazole and its main metabolite M2 was performed using a reversedexcept patient 6 received frusemide 160-375 mg/day. The daily antihypertensive medication was the following: subjects phase HPLC-method which was validated for pantoprazole [7] . Serum concentrations of pantoprazole were expressed 1 and 8, captopril (12.5 mg each); subject 3, nifedipine (5 mg); subject 6, nifedipine (60 mg), clonidine (450 mg), and as its Na salt. The limits of quantitation in plasma were 0.03 mg/l for pantoprazole-Na or 0.03 mg Eq/l for its main captopril (25 mg); subject 7, enalapril (2.5 mg). metabolite M2, respectively. M2 was quantified in relative tions of both pantoprazole and M2 were similar on concentration units of pantoprazole only since no synthetic the two study days. Consistently, the pharmacokinetic reference compound was available for full validation. characteristics derived thereof showed no relevant Analysis of urine or dialysis fluid samples was done ana-changes between the two study days for either comlogously, however, with direct injection of the samples onto pound. Intra-and interindividual variation of AUC of the HPLC column. The respective limits of quantitation in pantoprazole was small. urine were 0.1 mg/l for pantoprazole-Na or 0.1 mg Eq/l for M2. Corresponding values for dialysis fluid were 0.3 mg/l (pantoprazole) or 0.3 mg Eq/l (M2).
Pantoprazole-Na and metabolite M2 in urine
Pantoprazole-Na concentrations in urine were below Protein binding the limit of quantitation in all subjects on both study days. The amounts of excreted metabolite M2 were The protein binding of pantoprazole was determined in samples low, the maximum being 2.3% of the dose. taken at 15 min or 3 h post-dose on day 1 (without dialysis) by spiking each sample with 0.5 mg/l 14C-labelled pantoprazoleNa, followed by equilibrium dialysis for 5 h. Concentrations Pantoprazole-Na and metabolite M2 in dialysis fluid were measured using liquid scintillation counting.
Only small amounts of pantoprazole-Na were found in the dialysate, the maximum amount being 2.1% of Pharmacokinetic evaluation the dose. The median half-life of pantoprazole-Na in the dialysis fluid was 1.06 h. Metabolite M2 could not For pantoprazole-Na in plasma, area under the concentration be analysed in the dialysis fluid due to interferences. Pantoprazole was well tolerated. There were no relevant changes in clinical laboratory parameters (in parStatistics ticular plasma electrolytes or liver enzymes) nor in blood pressure or heart rate.
For pantoprazole-Na, the results of day A (without haemodialysis) were compared with day B (with haemodialysis) by means of distribution free ratio analysis. Point estimates and
Discussion
90% confidence limits are given for the ratio of the population medians day B/day A. As metabolite M2 is quantified on a relative scale only, no ratio analysis was performed for this Haemodialysis does not influence the plasma pharmcompound. All other data are presented descriptively.
acokinetics of pantoprazole or its main metabolite M2. Due to its comparable plasma concentrations and pharmacokinetic characteristics on the day with or
Results
without haemodialysis, only small amounts could be expected in the dialysis fluid. Consistently, only negliPlasma concentrations of pantoprazole-Na and gible amounts of pantoprazole were found in the metabolite M2 dialysis fluid. Thus pantoprazole is virtually not dialysable. Therefore, dialysis will not be helpful in case of Following intravenous 2-min injection, maximum plasma concentrations of pantoprazole were observed an overdose which, however, has not yet been experienced. Even at a dose of 240 mg injected once daily at the first measured timepoint (0.25 h). Plasma concentrations decreased monoexponentially with elimina-over 7 days [9] or a bolus injection of 80 mg followed by a long-term infusion of 8 mg/h over 3 days [10] tion half-lives of 0.63 h (without haemodialysis) or 0.80 h (with haemodialysis) respectively ( Table 2 ). Ten pantoprazole was well tolerated.
A comparison of the pharmacokinetic characteristics hours after injection, pantoprazole plasma concentrations were below the limit of quantitation on both of pantoprazole in this patient population with endstage renal failure and healthy volunteers from a study days. For the metabolite M2, maximum plasma concentrations of 1.40 mg Eq/l (without haemodia-previous study [4] shows lower AUC values and shorter elimination half-lives for this patient group. The lysis) or 1.36 mg Eq/l (with haemodialysis) were observed 0.75 h or 1.0 h after injection ( Table 3) . M2 shorter elimination half-life in patients with end-stage renal failure could be caused by the slightly lower was eliminated with half-lives of 2.7 or 3.0 h respectively. Twenty-four hours after dosing, M2 plasma protein-binding in this subpopulation (96%) as compared to healthy volunteers (98%). This could also concentrations were near or below the limit of quantitation. From Figure 1 it follows that plasma concentra-contribute to the slightly higher volume of distribution in patients with renal failure in comparison to normals ine clearance <20 ml/min) showed no relevant difference in the pharmacokinetic characteristics of pantobut in both the range overlaps considerably. Heparin during haemodialysis might additionally lead to a prazole and metabolite M2 in comparison to a matched group of healthy controls [11] . As pantoprazole has a displacement of pantoprazole from protein binding. The AUC of the metabolite M2 was higher in the low potential to interact with other drugs in man [2] , no influence of the current comedications on the patients with renal failure probably due to its decreased renal elimination. Nevertheless, no accumulation has pharmacokinetics of pantoprazole is to be expected.
As the pharmacokinetic characteristics of pantoprato be expected since plasma concentrations of M2 after 24 h were near or below the limit of quantitation in zole and its metabolite M2 are comparable without and with haemodialysis (using a low-flux dialysis memall patients (LOQ=0.03 mg Eq/l ).
The comparison of both studies in the different brane), and taking into account the safety and tolerability of pantoprazole in these patients, no dose groups has to take into account that they were not matched for age, sex, weight etc. Actually, an oral adjustment is required for patients with end-stage renal failure undergoing regular haemodialysis treatment. study in patients with severe renal impairment (creatin-
